Biotechgate Global Database ›
National Research Corporation Announces Third Quarter 2018 Results
LINCOLN, Neb., Nov. 06, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced results for the third quarter of 2018.
- Net New Sales of $6.2 million
- Revenue up 4% to $30 million
- Operating Income up 29% to $9.2 million
- Voice of Customer platform contract value increased to $37 million
- Third quarter platform revenue increased to 27% of total revenue, up from 15% in the same period 2017
Remarking on Company performance, Michael D. Hays, chief executive officer of National Research Corporation said, “We welcome MD Anderson, Johns Hopkins and Cedars-Sinai to our growing list of new and expanded NRC Health partners. In the third quarter alone, we exceeded the total dollar value of new client wins in all of 2017 and year-to-date, have more than doubled last year.”
Kevin Karas, chief financial officer commented, “Third quarter net new sales were 15% higher than the same period last year. We also realized much better customer retention which drove significant improvement in our revenue growth rate compared to the first half of 2018. Operating income increased by over $2.0 million compared to the prior year as a result of revenue growth leverage, operating efficiencies and the impact of $958,000 of recapitalization costs incurred in the third quarter of 2017.”
Revenue for the quarter ended September 30, 2018, was $30.0 million, compared to $29.0 million for the same quarter in 2017. Net income for the quarter ended September 30, 2018, was $7.0 million, compared to $4.2 million for the quarter ended September 30, 2017. Diluted earnings per share increased to $0.27 for the common shares (formerly Class A) for the quarter ended September 30, 2018, from diluted earnings per share of $0.09 for Class A shares and $0.57 for Class B shares for the quarter ended September 30, 2017. Due to the recapitalization transaction on April 17, 2018, income has been allocated to both classes of shares through April 16, and allocated only to common stock (formerly Class A) after April 16.
A listen-only simulcast of National Research Corporation’s 2018 third quarter conference call will be available online at http://edge.media-server.com/m6/p/v4h88sbd on November 7, 2018, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.
For more than 37 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. The Company’s solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth.
This press release includes “forward-looking” statements related to the Company that can generally be identified as describing the Company’s future plans, objectives or goals. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the factors that could affect the Company’s future results, please see the Company’s filings with the Securities and Exchange Commission.
Contact: Kevin R. Karas
Chief Financial Officer
402-475-2525
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||||
| Revenue | $ | 30,013 | $ | 28,951 | $ | 89,047 | $ | 87,661 | |||||||||||
| Operating expenses: | |||||||||||||||||||
| Direct expenses | 11,780 | 12,267 | 35,685 | 36,706 | |||||||||||||||
| Selling, general and administrative | 7,679 | 8,430 | 23,486 | 22,021 | |||||||||||||||
| Depreciation and amortization | 1,388 | 1,132 | 3,996 | 3,376 | |||||||||||||||
| Total operating expenses | 20,847 | 21,829 | 63,167 | 62,103 | |||||||||||||||
| Operating income | 9,166 | 7,122 | 25,880 | 25,558 | |||||||||||||||
| Other income (expense): | |||||||||||||||||||
| Interest income | 3 | 29 | 57 | 58 | |||||||||||||||
| Interest expense | (544 | ) | (18 | ) | (990 | ) | (68 | ) | |||||||||||
| Other, net | (242 | ) | 40 | 222 | 76 | ||||||||||||||
| Total other (expense) income | (783 | ) | 51 | (711 | ) | 66 | |||||||||||||
| Income before income taxes | 8,383 | 7,173 | 25,169 | 25,624 | |||||||||||||||
| Provision for income taxes | 1,391 | 3,020 | 2,923 | 9,198 | |||||||||||||||
| Net income | $ | 6,992 | $ | 4,153 | $ | 22,246 | $ | 16,426 | |||||||||||
| Earnings Per Share of Common Stock: | |||||||||||||||||||
| Basic Earnings Per Share: | |||||||||||||||||||
| Common (formerly Class A) | $ | 0.28 | $ | 0.10 | $ | 0.76 | $ | 0.39 | |||||||||||
| Class B | $ | -- | $ | 0.59 | $ | 1.31 | $ | 2.34 | |||||||||||
| Diluted Earnings Per Share: | |||||||||||||||||||
| Common (formerly Class A) | $ | 0.27 | $ | 0.09 | $ | 0.73 | $ | 0.38 | |||||||||||
| Class B | $ | -- | $ | 0.57 | $ | 1.27 | $ | 2.28 | |||||||||||
| Weighted average shares and share equivalents outstanding Common (formerly Class A) - basic | 24,671 | 20,788 | 23,184 | 20,759 | |||||||||||||||
| Class B - basic | -- | 3,514 | 3,527 | 3,514 | |||||||||||||||
| Common (formerly Class A) - diluted | 25,526 | 21,740 | 24,083 | 21,537 | |||||||||||||||
| Class B - diluted | -- | 3,620 | 3,628 | 3,595 | |||||||||||||||
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except per share amounts and par value)
Sep. 30, 2018 | Dec. 31, 2018 | ||||||
| ASSETS | |||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 7,273 | $ | 34,733 | |||
| Accounts receivable, net | 16,544 | 14,806 | |||||
| Income taxes receivable | 1,001 | 375 | |||||
| Other current assets | 3,952 | 2,345 | |||||
| Total Current Assets | 28,770 | 52,259 | |||||
| Property and equipment, net | 14,269 | 12,359 | |||||
| Goodwill | 57,955 | 58,021 | |||||
| Deferred contract costs | 3,371 | -- | |||||
| Other, net | 4,352 | 4,677 | |||||
| Total Assets | $ | 108,717 | $ | 127,316 | |||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
| Current Liabilities: | |||||||
| Accounts payable and accrued expenses | $ | 4,307 | $ | 3,546 | |||
| Deferred revenue | 18,642 | 16,878 | |||||
| Accrued compensation | 4,586 | 6,597 | |||||
| Dividends payable | 4,209 | 4,222 | |||||
| Income taxes payable | 70 | -- | |||||
| Notes payable | 3,623 | 1,067 | |||||
| Total Current Liabilities | 35,437 | 32,310 | |||||
| Non-Current Liabilities | 43,141 | 4,965 | |||||
| Total Liabilities | 78,578 | 37.275 | |||||
| Shareholders’ Equity: | |||||||
Preferred stock, $0.01 par value, authorized 2,000,000 shares, n
By: Nasdaq / GlobeNewswire
- 06 Nov 2018
Return to news
Partners
Upcoming Life Sciences Events
Latest company news
BioT Medical Awarded 2023 AWS Rising Star Partner of the Year
| |||||||
